ERBB2 and breast cancer: Moreover, elevated Siglec-7 expression was linked to aggressive breast cancer subtypes, notably HER2-enriched and Claudin-low TNBC, which are characterized by their high immunogenicity, evidenced by a greater infiltration of tumor-infiltrating lymphocytes (TILs) (11).